Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.9K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

8.5K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Retraction Note: NSD2 targeting reverses plasticity and drug resistance in prostate cancer.

Nature·2026
Same author

Drug Screening of Sarcoma Cells: Finding Shared Sensitivities.

Cancer research communications·2026
Same author

Decoding the Raf-Mek-Erk-Rsk pathway in prostate cancer: from molecular mechanisms to clinical opportunities.

British journal of cancer·2026
Same author

Immune Spatial Organization Predicts Distant Metastasis Risk in Aggressive Localized Prostate Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Phase I trial of Ipatasertib plus Atezolizumab enhances PI3K/AKT pathway immune responses in solid tumors and refractory glioblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Suppression of de novo lipogenesis and dietary PUFA supplementation inhibit prostate cancer progression.

bioRxiv : the preprint server for biology·2026

相关实验视频

Updated: Jul 2, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K

提奥-2 抑制了关键的信号通路,这些通路对抗割的前列腺癌的发展和进展是必需的.

Antje Neeb1, Ines Figueiredo1, Denisa Bogdan1

  • 1Institute of Cancer Research, London, United Kingdom.

Molecular cancer therapeutics
|February 27, 2024
PubMed
概括
此摘要是机器生成的。

向BCL-2-关联的乙基-1 (BAG-1) 对割抵抗性前列腺癌 (CRPC) 显示出希望. 用Thio-2抑制BAG-1抑制瘤生长,这表明CRPC的新治疗途径.

更多相关视频

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.4K
Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

45.7K

相关实验视频

Last Updated: Jul 2, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.4K
Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

45.7K

科学领域:

  • 在瘤学瘤学.
  • 分子生物学分子生物学
  • 药物发现 药物发现 药物发现

背景情况:

  • 化抵抗性前列腺癌 (CRPC) 的进展是由持续的雄激素受体 (AR) 信号驱动的.
  • 对于CRPC疗法来说,ARN终端域是一个具有挑战性的目标.
  • 在CRPC中,BCL-2-关联的乙基-1 (BAG-1) 具有很高的表达,并且与AR信号传递有关.

研究的目的:

  • 在CRPC中研究BAG-1作为治疗点.
  • 在临床前CRPC模型中评估BAG-1抑制的疗效.
  • 探索BAG-1异型在前列腺癌进展中的作用.

主要方法:

  • 在CRPC中分析BAG-1mRNA表达.
  • 对BAG-1的BAG域属性的审讯,用于药物向.
  • 在BAG-1异形小鼠中进行了淘汰赛研究.
  • 治疗CRPC细胞系和患者衍生模型的Thio-2,一个BAG-1抑制剂.

主要成果:

  • BAG-1的表达很高,并且与CRPC中的AR信号相关.
  • BAG-1异型调节激素生理学,具有有限的目标毒性潜力.
  • 蒂奥-2抑制了AR信号传递和其他关键途径,减少了治疗耐药前列腺癌的生长.
  • BAG-1的基因组废除无法完全复制Thio-2的影响,这表明了复杂的机制.

结论:

  • 在CRPC中,BAG-1是一个可用药的目标.
  • 提奥-2通过抑制AR信号和减少瘤生长来证明其治疗潜力.
  • 对具有改善性质的BAG-1抑制剂进行进一步的研究对于CRPC治疗是有必要的.
  • 针对持久性AR信号仍然是CRPC治疗中的关键策略.